Acción ENLV ENLIVEX THERAPEUTICS LTD.
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Enlivex Therapeutics Ltd.

Acciones

ENLV

IL0011319527

Mercado cerrado - Nasdaq
Otros sitios de cotización
 22:30:00 26/06/2024 		Varia. Cinco días. Varia. 1 de enero.
1,37 USD +0,74 % Gráfico intradía de Enlivex Therapeutics Ltd. +6,20 % -49,26 %
24/06 Enlivex Therapeutics dice que se ha administrado la dosis al primer paciente en el ensayo de fase 1/2 sobre osteoartritis del pulgar MT
24/06 Enlivex Therapeutics Ltd. Anuncia la dosificación del primer paciente en un ensayo de fase I/II aleatorizado y controlado con placebo que evalúa AllocetraTM en hasta 46 pacientes con osteoartritis del pulgar CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias sobre todas las empresas: ¡No vuelvas a perderse una oportunidad de inversión rentable!
Inscripción 100% Gratuita
Enlivex Therapeutics Says First Patient Dosed in Phase 1/2 Thumb Osteoarthritis Trial
Enlivex Therapeutics : Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating Allocetra in up to 46 Patients with Thumb Osteoarthritis
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics Ltd. Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2024 AND DECEMBER 31, 2023 AND FOR THE THREE MONTH PERIODS ENDED MARCH 31, 2024 AND 2023 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Form 6 K
Enlivex Therapeutics Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
Enlivex Therapeutics : Immediate Report
Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
Enlivex Therapeutics to Launch Registered Direct Offering; Shares Fall
Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
Enlivex Therapeutics : Report of Periodic or Interim Report
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción ENLV
  4. Noticias Enlivex Therapeutics Ltd.
  5. Otros idiomas